High frequency of IMP-6 among clinical isolates of metallo-β- lactamase-producing Escherichia coli in Japan

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4554-4555

  Yano, Hisakazu ^a   Ogawa, Miho ^a   Endo, Shiro ^a   Kakuta, Risako ^a   Kanamori, Hajime ^a   Inomata, Shinya ^a   Ishibashi, Noriomi ^a   Aoyagi, Tetsuji ^a   Hatta, Masumitsu ^a   Gu, Yoshiaki ^a   Yamada, Mitsuhiro ^a   Tokuda, Koichi ^a   Kunishima, Hiroyuki ^a   Kitagawa, Miho ^a   Hirakata, Yoichi ^a   Kaku, Mitsuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METALLO BETA LACTAMASE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN IMP 6; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIUM ISOLATE; ENZYME ANALYSIS; ESCHERICHIA COLI; JAPAN; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS;

EID: 84864387138     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00617-12     Document Type: Letter

References (12)

1. Baldwin CM, Lyseng-Williamson KA, Keam SJ. 2008. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 68:803-838. (Pubitemid 351559562)
2. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-8th edition. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Hirakata Y, et al. 1998. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-β-lactamase gene blaIMP. Antimicrob. Agents Chemother. 42:2006-2011. (Pubitemid 28363084)
5. Kanamori H, et al. 2011. High prevalence of extended-spectrum β-lactamases and qnr determinants in Citrobacter species from Japan: dissemination of CTX-M-2. J. Antimicrob. Chemother. 66:2255-2262.
6. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. 1999. Worldwide proliferation of carbapenem-resistant gram-negative bacteria. Lancet 354:955. doi:10.1016/S0140-6736(05)75707-X. (Pubitemid 29424044)
7. Nishio H, et al. 2004. Metallo-β-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan. J. Clin. Microbiol. 42:5256-5263. (Pubitemid 39506238)
8. Queenan AM, Bush K. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440-458.
9. Seok Y, et al. 2011. Dissemination of IMP-6 metallo-β- lactamaseproducing Pseudomonas aeruginosa sequence type 235 in Korea. J. Antimicrob. Chemother. 66:2791-2796.
10. Shigemoto N, et al. 2012. Emergence in Japan of an imipenem-susceptible, meropenem-resistant Klebsiella pneumoniae carrying blaIMP-6. Diagn. Microbiol. Infect. Dis. 72:109-112.
11. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64:233-235.
12. Yano H, et al. 2001. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob. Agents Chemother. 45:1343-1348. (Pubitemid 32374100)